Clinical trial NCT04024553: A Genetic Family Cohort Study of Bipolar Disorder in Chinese Han Population
Official title: A Genetic Family Cohort Study of Bipolar Disorder in Chinese Han Population
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Bipolar Disorder
Keywords: bipolar disorder
family
genetic
Lead sponsor: Shanghai Mental Health Center
Sponsor class: OTHER
First posted: 2019-07-18
Enrollment: 2520
Sex: ALL
Minimum age (years): 15
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: We intend to expand the sample size of the family, and collect 50 core families and 200 healthy controls at this stage. Similarly, during the validation phase, it is proposed to include 30 core families for verification.

To verify the results of the first part of the study in sporadic BD patients and healthy controls, 783 patients with sporadic BD and 692 healthy controls were calculated by sample size estimation formula. With drop-off rate of 20%, 939 cases and 830 cases are needed respectively. In order to avoid other factors falling off, it is proposed to include 1000 cases of sporadic BD patients and healthy controls respectively.

Brief summary: This study intends to find out the pathogenic genes of bipolar disorder by collecting the two-phase family of Chinese Han population with the large sample using a family cohort study design, combined with the new generation of high-throughput sequencing technology and Genome-Wide Association Studies (GWAS), Proteomics, bioinformatics analysis, etc., which is expected to be clarified at the genetic level. The pathogenesis of bipolar disorder. At the same time, the investigators will conduct a five-year follow-up of cognitive function, brain function imaging and other major clinical symptoms in patients with bipolar disorder in the core family, and to explore familial bipolar disorder and sporadic biphasic. Differences in the clinical features of the disorder, in order to explore sensitive and specific biomarkers from a multidimensional perspective (cognitive function, brain imaging, genetic features, clinical features, etc.), which may contribute to bipolar disorder in the future. Accurate diagnosis and early identification and prevention have important scientific significance and clinical diagnosis and treatment significance.

Detailed description: Bipolar disorder (BD) is a serious, complex, family-grafting mental illness. Studies have shown that genetic factors may be the dominant factor in the pathogenesis of bipolar disorder, thus, it is worth looking forward to getting started and clarifying the etiology of bipolar disorder from a genetic perspective. However, earlier genetic studies such as linkage analysis, genetic mutation detection (preferred candidate genes), and recent genetic studies (no need to presuppose candidate genes) such as Whole Genome Sequencing (WGS), whole genome GWAS and Whole-exome sequencing (WES) failed to identify any biogenic disorder gene or chromosomal region that plays a major role in, which may be related to the synergy of population heterogeneity, insufficient sample size or coordination effect caused by common mutations.

As a familial, highly heritable psychiatric disease, the literature suggests that the pathogenic genes of bipolar disorder may be directly derived from the intergenerational transmission of rare mutations in family members, and these rare variants are more likely to be predicated from the family. It has been found that the family has a higher frequency and is more susceptible to detecting susceptibility genes for bipolar disorder. Therefore, the family research design combined with WGS, GWAS and other advanced genetic research methods can reduce the unnecessary sample size, eliminate the confounding factors of the population, and more easily capture the potential genes of bipolar disorder.

However, at present, there are few reports of foreign bipolar disorder family and the results are not consistent. There is no research report on the large sample family of Chinese Han population in China. Therefore, it is necessary to expand the family sample size and combine with new genetic research methods in the Han population. explore. Therefore, this study intends to find out the pathogenic genes of bipolar disorder by collecting the two-phase family of Chinese Han population with the large sample using a family cohort study design, combined with the new generation of high-throughput sequencing technology and GWAS, Proteomics, bioinformatics analysis, etc., which is expected to be clarified at the genetic level. The pathogenesis of bipolar disorder. At the same time, the investigators will conduct a five-year follow-up of cognitive function, brain function imaging and other major clinical symptoms in patients with bipolar disorder in the core family, and to explore familial bipolar disorder and sporadic biphasic. Differences in the clinical features of the disorder, in order to explore sensitive and specific biomarkers from a multidimensional perspective (cognitive function, brain imaging, genetic features, clinical features, etc.), which may contribute to bipolar disorder in the future. Accurate diagnosis and early identification and prevention have important scientific significance and clinical diagnosis and treatment significance.

Eligibility criteria: Inclusion Criteria:

* BD patients from BD family:

  1. Meets the diagnostic criteria of BD in DSM-IV-TR, does not limit subtypes and current disease status;
  2. age ≥ 15 years old;
  3. Han nationality;
  4. There are enough audition levels to complete the necessary examinations for the study;
  5. Understand the research content and sign the informed consent form. If the patient is unable to sign the informed consent form due to the young age, senior age, low education level or other reasons, they can be signed by their relatives or signed by their guardian.
* Healthy menbers from BD family:

  1. age ≥ 15 years old;
  2. Han nationality;
  3. biological parents or compatriots of the proband, cousins;
  4. There are enough audition levels to complete the necessary examinations for the study;
  5. Understand the research content and sign the informed consent form. If the patient is unable to sign the informed consent form due to the young age, senior age, low education level or other reasons, they can be signed by their relatives or signed by their guardian.
* Healthy control enrollment criteria without family history:

  1. age ≥ 15 years old;
  2. Han nationality;
  3. gender matches the patient group in the family;
  4. There are enough audition levels to complete the necessary examinations for the study;
  5. Understand the research content and sign the informed consent form. If the patient is unable to sign the informed consent form due to his or her age, advanced age, low education level or other reasons, he or she may be entrusted to sign by his or her relatives or signed by his guardian;

Exclusion Criteria:

* BD patients from BD family:

  1. There is a DSM-IV-TR axis II disease (mental retardation, etc.) that significantly affects the patient's current state of mind;
  2. There are serious physical diseases, it is difficult to complete the necessary examinations, including history of brain trauma or cerebrovascular disease, severe cirrhosis, acute and chronic failure, severe diabetes, aplastic anemia, moderate to severe malnutrition and other serious nerves, heart, Physical diseases such as liver, kidney, endocrine, and blood system or diseases that may interfere with the test evaluation (the abnormal index is more than 2 times higher than the normal value).
* Healthy menbers from BD family and healthy control enrollment criteria without family history::

  1. with a mental disorder that meets the diagnostic criteria for DSM-IV-TR axis I or who have suspected psychosis but do not meet the diagnostic criteria;
  2. There are DSM-IV-TR axis II diseases (mental retardation, etc.) that significantly affect the patient's current mental state;
  3. There are serious physical illnesses, and it is difficult to complete the necessary examinations.

Primary outcomes:
measure: Potential risk genes
timeFrame: at december 2022
Secondary outcomes:
measure: HAMD-17 scores of patients and high-risk subjects
timeFrame: by december 2022
measure: Onset age of BD subjects
timeFrame: by december 2022
measure: Wisconsin Card Sorting Test results
timeFrame: by december 2022
measure: Characteristic changes of electroencephalogram
timeFrame: by december 2022
measure: YMRS scores of patients and high-risk subjects
timeFrame: by december 2022
measure: Course of disease of BD subjects
timeFrame: by december 2022
measure: Treatment plan of BD subjects
timeFrame: by december 2022
measure: STROOP test results
timeFrame: by december 2022
measure: Repetitive Neuropsychological Status test (RBANS) results
timeFrame: by december 2022
Other outcomes:
Locations:
city: Shanghai
country: China
facility: Shanghai Mental Health Center
state: Shanghai
Study officials:
affiliation: Shanghai Mentao Health Center
name: Yiru Fang
role: PRINCIPAL_INVESTIGATOR
References: